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Background {#onco13280-sec-0001}
==========

Immune‐related adverse events (irAEs) represent a unique class of toxicity associated with immune checkpoint inhibitor (ICI) targeting of anti‐programmed death 1 (PD1), PD1 ligand (PDL1), or cytotoxic T‐lymphocyte antigen 4 (CTLA4). These autoimmune toxicities can potentially affect almost every organ system. With combination regimens, up to 85% of patients may develop irAEs, and more than 40% of patients may discontinue treatment because of these toxicities [1](#onco13280-bib-0001){ref-type="ref"}.

Adding to this challenge, the occurrence, type, severity, and timing of irAEs remain unpredictable. There are no established clinical or serologic biomarkers for the identification of patients at high risk for toxicity. Biomarkers under investigation include pre‐existing systemic and organ‐specific autoantibodies, including antithyroidal antibodies [2](#onco13280-bib-0002){ref-type="ref"}, as well as peripheral blood cellular ratios [3](#onco13280-bib-0003){ref-type="ref"}.

We present a case of a patient with advanced non‐small cell lung cancer treated with combined anti‐CTLA4 and anti‐PD1 checkpoint blockade who derived long‐term benefit. The patient developed a late‐onset rheumatologic irAE after more than 20 months. The presented serial autoantibody levels may provide insight into the humoral immunity underlying this delayed toxicity.

Case Presentation {#onco13280-sec-0002}
=================

A 53‐year‐old woman with a 35 pack‐year smoking history developed progressive mid‐back pain. She was found to have a paraspinal mass, multiple bilateral pulmonary nodules, and a dominant 1.7‐cm right lower lobe mass. Biopsy revealed adenocarcinoma consistent with lung primary, harboring a *KRAS* ^G12C^ mutation. The patient had no history of autoimmune disease. She initiated combination ipilimumab 1 mg/kg intravenously (IV) every 6 weeks and nivolumab 3 mg/kg IV every 2 weeks and was transitioned to nivolumab 480 mg IV every 4 weeks as consolidation therapy after 28 months.

After 4 months of therapy, she developed weakness, fatigue, and orthostatic hypotension. Laboratory assessment revealed low serum concentrations of adrenocorticotropic hormone (\<5 pg/mL) and cortisol (0.8 μ/dL). She was diagnosed with hypophysitis featuring secondary adrenal insufficiency. She improved with hydrocortisone.

After 22 months, she noted an abnormal, painful cold sensation in her fingers and toes, which turned white upon cold exposure and then red upon rewarming (Fig. [1](#onco13280-fig-0001){ref-type="fig"}). She was diagnosed with Raynaud\'s‐like phenomenon, which improved with behavior modification and treatment with calcium channel blockers.

![Images of patient\'s Raynaud\'s episode during cold and rewarming.](ONCO-25-e753-g001){#onco13280-fig-0001}

Immunotherapy was continued without interruption throughout this period. Regarding efficacy, the patient achieved a deep partial (near complete) radiographic response, which had been sustained for more than 38 months after treatment initiation at the time of this report.

Autoantibody Analysis {#onco13280-sec-0003}
=====================

Prior to therapy initiation, the patient was enrolled in a prospective biospecimen collection protocol (Institutional Review Board STU 082015‐053). Peripheral blood samples were collected from the patient at pretreatment baseline and throughout therapy. Unfortunately, samples were not collected beyond the onset of Raynaud\'s‐like symptoms.

Autoantigen Array Analysis {#onco13280-sec-0004}
--------------------------

As described previously [4](#onco13280-bib-0004){ref-type="ref"}, we measured autoantibody reactivates against a panel of 124 autoantigens using a microarray platform developed by the Microarray Core at UT Southwestern. The panel, designed by Q.‐Z.L. and E.K.W., includes autoantibodies associated in the literature with a broad range of autoimmune and inflammatory conditions. Briefly, diluted serum samples were incubated with the autoantigen arrays, and autoantibodies were detected with cy3‐conjugated anti‐mouse immunoglobulin (Ig)G and cy5‐conjugated anti‐mouse IgM (1:2,000, Jackson ImmunoResearch Laboratories, West Grove, PA), using a Genepix 4200A scanner (Molecular Devices, San Jose, CA) with laser wavelength of 532 nm and 635 nm. The resulting images were analyzed using Genepix Pro 7.0 software (Molecular Devices). The net fluorescence intensity of each autoantibody was used to generate heatmaps using Cluster and Treeview software [5](#onco13280-bib-0005){ref-type="ref"}.

Additionally, in this case, serum antinuclear antibody (ANA) titers were assessed at each time point in duplicates across 96‐microwell ANA enzyme‐linked immunosorbent assay (ELISA) plates using Quanta Lite ANA ELISA kits by Inova Diagnostics (San Diego, CA).

Results {#onco13280-sec-0005}
=======

Hierarchical clustering of 124 autoantibodies demonstrated dynamic changes in serum levels of multiple autoantibodies throughout immunotherapy (Fig. [2](#onco13280-fig-0002){ref-type="fig"}A). Notably, meaningful increases in antibody levels did not occur until more than 1 year after treatment initiation, with the greatest changes noted after month 18. After 21 months, weeks before the emergence of Raynaud\'s phenomenon, we observed a rise in multiple autoantibody levels, including antivitronectin, anti‐β2 glycoprotein, antiprothrombin, antiangiotensin receptor 2 type 1, and anti‐double‐stranded DNA (Fig. [2](#onco13280-fig-0002){ref-type="fig"}B). ANA levels were not elevated at baseline or at any time point after treatment initiation (data not shown). Anticentromere antibodies had a modest and sustained increase throughout therapy (CENPB in Fig. [2](#onco13280-fig-0002){ref-type="fig"}A).

![Longitudinal autoantibody analysis. **(A):** Heatmap of 124 autoantibodies at eight time points. **(B):** Serum levels of selected autoantibodies associated with Raynaud\'s phenomenon over time. At BL, 4 months, 13 months, and 21.5 months (shortly before development of clinical features of Raynaud\'s). Values on *y*‐axis represent net fluorescence intensity as described in methods. Abbreviations: BL, baseline; dsDNA, double‐stranded DNA; mo, months.](ONCO-25-e753-g002){#onco13280-fig-0002}

Discussion {#onco13280-sec-0006}
==========

Unlike characteristic toxicities of conventional chemotherapy and molecularly targeted therapies, which have relatively predictable onset and duration, irAEs may occur at any point throughout treatment. Serious irAEs have been reported as early as after a single dose of ICI and as late as several months after treatment discontinuation [6](#onco13280-bib-0006){ref-type="ref"}. For rheumatic irAEs---a category that would encompass this patient\'s Raynaud\'s‐like symptoms---reported onset ranges from 2 to 13 months after initiating checkpoint inhibitor therapy [7](#onco13280-bib-0007){ref-type="ref"}.

Although cases of digital ischemia have been reported in the setting of immunotherapy [8](#onco13280-bib-0008){ref-type="ref"}, to our knowledge this is the first description of ICI‐induced Raynaud\'s‐like symptoms. The occurrence of Raynaud\'s almost 1 year later than the latest‐onset rheumatic irAE described previously [7](#onco13280-bib-0007){ref-type="ref"} highlights the truly unpredictable nature of these events and the importance of not relying exclusively on earlier published experience to guide suspicion for and evaluation of potential irAEs. Although Raynaud\'s symptoms are far preferable to progressive, advanced malignancy, this case does raise theoretical questions about the optimal duration of immunotherapy in individuals with prolonged clinical benefit.

The delayed Raynaud\'s symptoms may reflect humoral stimulation, which in turn leads to increased autoantibody production. The temporal relationship between autoantibody changes and symptom onset suggests the possibility that these autoantibodies may be involved in the Raynaud\'s pathophysiology. For instance, vitronectin regulates cell adhesion and proteolysis in the vascular extracellular matrix [9](#onco13280-bib-0009){ref-type="ref"}. Antivitronectin antibodies may prevent smooth muscle migration, leading to dysfunctional vascular tone, immune‐mediated vasculitis, and vasoconstriction [10](#onco13280-bib-0010){ref-type="ref"}, [11](#onco13280-bib-0011){ref-type="ref"}. We did note a particularly profound increase in antivitronectin antibodies prior to toxicity, which target endothelial cell function. One might hypothesize a potential mechanistic link between these antibodies and the clinical vasoconstriction experienced by the patient in this case report. However, antivitronectin antibodies have not been associated with Raynaud\'s phenomenon historically, and their elevation in this particular case does not necessarily indicate mechanistic causality. Indeed, Raynaud\'s phenomenon lacks a well‐defined serologic profile. ANA---negative throughout the clinical course in this patient---is positive in only 50% of cases [12](#onco13280-bib-0012){ref-type="ref"}. Anticentromere antibodies---elevated and increasing over time in this case---are positive in approximately one third of cases and are associated with greater clinical severity [13](#onco13280-bib-0013){ref-type="ref"}. This leads us the following conclusions: either (a) the antivitronectin antibodies are coincidental and unrelated or, (b) as has been suggested of multiple irAEs, these events resemble the associated autoimmune disease but may not have the same pathophysiology [14](#onco13280-bib-0014){ref-type="ref"}.

Notably, we observed no substantial autoantibody changes at the time of hypophysitis, suggesting either that this event did not involve humoral immune changes or that our panel did not capture the relevant autoantibodies. Alternatively, it has been reported that hypophysitis may arise from the direct interaction between anti‐CTLA4 agents and CTLA4 expressed by pituitary cells [15](#onco13280-bib-0015){ref-type="ref"}.

We recognize the lack of antibody data after the development of Raynaud\'s like symptoms in this case as a key limitation. Immune profiling during the post‐toxicity time period hypothetically could have relevance to key clinical questions, including ICI treatment decisions (continue, withhold, or discontinue) and the dose and duration of steroids or other immunosuppressive agents.

Conclusion {#onco13280-sec-0007}
==========

The development of a late‐onset irAE in this case reinforces the importance of continuous and close monitoring of patients receiving immunotherapy. Although pretreatment autoantibody profiles have been associated with subsequent development of certain irAEs, the delayed emergence of potentially relevant autoantibodies presented here suggests that baseline assessments may not fully capture predisposition to autoimmune toxicity. As clinicians and investigators seek to determine the optimal duration of ICI therapy, consideration of the timing of antitumor and anti‐self‐immune responses will be critical.
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